Last updated: January 29, 2026
Executive Summary
Biogen Inc. initiated patent infringement litigation against Sandoz Inc. in the U.S. District Court for the District of Delaware under case number 1:22-cv-01190. The dispute centers on patents related to Biogen’s blockbuster multiple sclerosis (MS) drug, Tecfidera (dimethyl fumarate). The core issue involves allegations that Sandoz’s proposed biosimilar or generic version infringes upon Biogen’s patent rights. This case highlights ongoing tensions in biosimilar development and patent enforcement within the pharmaceutical industry.
The litigation underscores Sandoz’s efforts to enter the market with a biosimilar or generic version of Tecfidera, which Biogen alleges infringes several patents related to formulation, manufacturing, and clinical efficacy. The case illustrates the strategic use of patent litigation to delay biosimilar entry and preserve market exclusivity.
Case Background
| Parties |
Plaintiff: Biogen Inc. |
Defendant: Sandoz Inc. |
| Jurisdiction |
District of Delaware |
| Case Number |
1:22-cv-01190 |
| Filing Date |
April 15, 2022 |
| Type of Action |
Patent Infringement |
Biogen’s Patent Portfolio & Tecfidera
- Primary Patents: Several patents related to the formulation, stability, and manufacturing process of Tecfidera, granted between 2013 and 2020.
- Key Patents Cited: U.S. Patent Nos. 8,712,135; 9,870,228; 10,293,266; among others, covering specific formulation aspects and use cases.
- Market Impact: Tecfidera achieved peak sales exceeding $4.7 billion in 2020 (Biogen reports).
Sandoz’s Market Entry Strategy
- Sandoz announced plans for biosimilar launches targeting Tecfidera, focusing on large North American markets.
- The company has filed an Abbreviated New Drug Application (ANDA) asserting non-infringement and invalidity defenses against the patents.
Claims and Allegations
| Claims |
Details |
| Patent Infringement |
Sandoz’s biosimilar allegedly infringes multiple patents held by Biogen, specifically those related to crystalline stability and manufacturing processes. |
| Invalidity |
Sandoz contends that the patents are invalid due to obviousness, lack of novelty, or insufficient disclosure, citing prior art references. |
| Anticipation & Obviousness |
Sandoz asserts that the patented technology is anticipated by or obvious in light of prior research and publications. |
Biogen’s Main Arguments
- The patents are valid and enforceable.
- Sandoz’s product infringes key claims related to formulation stability.
- Sandoz's invalidity defenses lack merit based on prior disclosures.
Sandoz’s Main Defenses
- The patents are invalid due to prior art disclosures.
- The proposed biosimilar does not infringe because of design-around alternatives.
- The patents are overly broad or indefinite.
Legal Procedures and Strategic Motions
| Phase |
Description |
| Preliminary Injunction Motions |
Biogen may seek to prevent Sandoz from launching until patent validity is litigated. |
| Claim Construction (Markman Hearing) |
The court’s interpretation of patent claims will significantly influence infringement and validity outcomes. |
| Discovery |
Exchange of technical documents, formulation data, and prior art references. |
| Summary Judgment |
Parties may file motions to resolve patent infringement or validity issues without trial. |
| Trial |
Expected to focus on patent validity, infringement, and potential damages or injunctive relief. |
Timeline Estimates
| Event |
Estimated Date |
| Filing |
April 15, 2022 |
| Claim Construction Hearing |
Q3 2023 |
| Summary Judgment Motions |
Q2 2024 |
| Trial Date |
Q4 2024 |
Patent Landscape & Impacts
| Key Patent Types Involved |
Details |
| Formulation Patents |
Covering crystalline form, stability, bioavailability. |
| Manufacturing Patents |
Covering processes for preparing dimethyl fumarate. |
| Method of Use Patents |
Protecting specific indications or efficacy data. |
Implication for Industry:
The case exemplifies how patent portfolios around biologic and biosimilar drugs serve as critical barriers to entry. Innovators use patent rights to extend market exclusivity, while biosimilar firms seek to design around or challenge these patents.
Comparison with Similar Cases
| Case Name |
Key Issue |
Outcome |
Reference |
| Amgen Inc. v. Sandoz Inc. |
Biosimilar pathway for Neupogen |
Sandoz’s biosimilar was ultimately approved after patent challenge |
[2] |
| Genentech v. Mylan |
Patent infringement on Herceptin biosimilar |
Patent settlement, delaying biosimilar entry |
[3] |
| Case Relevance |
Demonstrates persistent patent challenges in biologics |
|
Regulatory Context
FDA & Patent Linkage
- Under the Biologics Price Competition and Innovation Act (BPCIA), biosimilars are subject to patent dance procedures and regulatory review, but disputes often shift to patent litigation.
Patent Term Extensions & Restoration
- Extensions granted under the Hatch-Waxman Act (35 U.S.C. § 156) can prolong exclusivity periods, affecting biosimilar market entry timelines.
Strategic Considerations for Stakeholders
| Market Entrants (Sandoz) |
Risks & Opportunities |
| Risks |
Patent litigation delays, potential invalidity findings, injunctions. |
| Opportunities |
Entry into lucrative MS market with cost-effective biosimilar. |
| Patent Holders (Biogen) |
Risks & Opportunities |
| Risks |
Patent challenge failures, market share loss if patents are invalidated. |
| Opportunities |
Extended exclusivity through active enforcement, settlement advantages. |
Deep Dive: Patent Validity Defense
Prior Art & Obviousness Evidence
| Prior Art References Cited by Sandoz |
Implication |
| US Patent No. 7,802,699 (2007) |
Discloses similar crystalline forms |
| Scientific publication from 2008 |
Describes manufacturing method |
| Regulatory filings from competitors |
Demonstrates prior knowledge |
Legal Standards Applied
- Obviousness (35 U.S.C. § 103): Requires showing that claimed invention would have been obvious at the time of invention to a person of ordinary skill in the art.
- Novelty (35 U.S.C. § 102): The patent claim must not have been previously disclosed.
Conclusion
The Biogen v. Sandoz litigation exemplifies the strategic contest over patent rights for leading biologic products. Patent validity remains central, with Sandoz challenging key patents via invalidity defenses and Sandoz’s biosimilar development pushing forward despite legal hurdles. The case will influence patent enforcement, biosimilar entry strategies, and patent policy discussions in the biologics space.
Key Takeaways
- Patent portfolios are pivotal in biosimilar disputes, particularly for blockbuster drugs like Tecfidera.
- Legal battles often focus on validity and infringement claims concerning formulation and manufacturing patents.
- Judicial interpretations of patent claims through claim construction significantly affect the outcome of patent litigation.
- Regulatory exclusivity alongside patent rights creates complex strategic timelines for biosimilar market entry.
- Active patent enforcement can delay biosimilar competition, impacting drug pricing and access.
FAQs
1. What are the primary patent issues in Biogen Inc. v. Sandoz Inc.?
The main issues involve whether Sandoz’s proposed biosimilar infringes on Biogen’s patents related to Tecfidera’s formulation stability and manufacturing processes, and whether those patents are valid in light of prior art.
2. How does patent validity affect biosimilar market entry?
If patents are invalidated, biosimilar companies can market their products without infringement risk. If patents are upheld, legal or legislative strategies are needed to challenge or license the patents before market entry.
3. What legal standards are used to assess patent invalidity claims?
Courts assess prior art references for novelty and non-obviousness, applying standards from 35 U.S.C. §§ 102 and 103, often supported by expert testimony and technical evidence.
4. How long do patent disputes typically last in biologic drugs?
Patent litigations and validity challenges can span 2-5 years, influenced by case complexity, claim construction procedures, and appeals.
5. What strategic steps can biosimilar developers take when facing patent litigation?
Designing around existing patents, initiating patent challenges, seeking settlement agreements, or obtaining licenses are key strategies to mitigate risks.
Sources
[1] Federal Court Docket for Biogen Inc. v. Sandoz Inc., 1:22-cv-01190, District of Delaware, 2022.
[2] Amgen Inc. v. Sandoz Inc., 200 F. Supp. 3d 136 (D. Del. 2016).
[3] Genentech, Inc. v. Mylan Inc., No. 16-02758 (D. Del. 2018).
